Bioextrax (BIOEX) Q3 2025 earnings summary

Executive summary

• Focus on commercializing bioplastics and protein/fiber technologies for sustainability, with strategic partnerships in multiple industries and a clear path toward full-scale licensing agreements for large-scale production.

• Ongoing industrialization supported by a 1,000-liter scale production facility, enabling faster customer validation and commercial traction.

• Planned fully guaranteed rights issue of approximately 13.3 MSEK to strengthen commercial capacity and support continued development and process optimization.

Financial highlights

• Q3 2025 net sales: 227 tkr (223 tkr Q3 2024); operating loss: -4,354 tkr (-3,747 tkr Q3 2024); EPS: -0.11 SEK (-0.11 SEK Q3 2024).

• Jan–Sep 2025 net sales: 754 tkr (393 tkr Jan–Sep 2024); operating loss: -12,789 tkr (-13,451 tkr Jan–Sep 2024); EPS: -0.32 SEK (-0.42 SEK Jan–Sep 2024).

• Cash flow Jan–Sep 2025: -9,347 tkr (-4,375 tkr Jan–Sep 2024); cash and cash equivalents at period end: 7,920 tkr (17,267 tkr Dec 2024).

• Equity per share at period end: 0.34 SEK (0.67 SEK Dec 2024); equity ratio: 84.92% (89.87% Dec 2024).

Outlook and guidance

• Board assesses that, with the planned rights issue, liquidity will be sufficient for the next 12 months.

• Focus on expanding commercial presence, accelerating licensing, and supporting customer projects toward full-scale agreements.